Results 41 to 50 of about 181,758 (302)
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
New England Journal of Medicine, 2014 BACKGROUND In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third ...
T. King +16 more
semanticscholar +1 more source
Akt1 regulates pulmonary fibrosis via modulating IL-13 expression in macrophages
Innate Immunity, 2019 Idiopathic pulmonary fibrosis is a progressive interstitial pneumonia characterised by fibroblast accumulation, collagen deposition and extracellular matrix (ECM) remodelling.
Yunjuan Nie +7 more
doaj +1 more source
IDIOPATHIC PULMONARY FIBROSIS. CORRECTION OF ERRORS
Вестник рентгенологии и радиологии, 2018 Substantial changes have been recently made in the concept of the diagnosis of idiopathic pulmonary fibrosis. The concept of disease pathogenesis and the pathomorphologic criteria for diagnosing usual interstitial pneumonia have been revised.
A. L. Yudin +2 more
doaj +1 more source
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
New England Journal of Medicine, 2014 BACKGROUND Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations
L. Richeldi +22 more
semanticscholar +1 more source
BMC Cancer, 2022 Background Idiopathic pulmonary fibrosis (IPF) is the most common type of interstitial pneumonia. Lung cancer, mainly non-small cell lung cancer (NSCLC), is a complication of idiopathic pulmonary fibrosis.
Wenxin Kou +7 more
doaj +1 more source
International Journal of Occupational Medicine and Environmental Health, 2017 Objectives: Idiopathic pulmonary fibrosis (IPF) (J84.1 by the International Statistical Classification of Diseases and Related Health Problems, 10th revision – ICD-10) is a rare disease of unknown cause.
Ewa Niewiadomska +2 more
doaj +1 more source
A review of current studies on cellular and molecular mechanisms underlying pulmonary fibrosis induced by chemicals [PDF]
Environmental Health and Toxicology, 2018 Several studies showed that the inflammatory and fibrotic responses induced by polyhexamethylene guanidine phosphate (PHMG-p) were similar to those observed for idiopathic pulmonary fibrosis in South Korea in 2011.
Ha Ryong Kim +2 more
doaj +1 more source
Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique. [PDF]
, 2015 © 2015, The Author(s).Introduction: There is a lack of agreed and established guidelines for the treatment of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF).
Bennett, BM +8 more
core +2 more sources
Survival Analysis for Idiopathic Pulmonary Fibrosis using CT Images and Incomplete Clinical Data [PDF]
arXiv, 2022 Idiopathic Pulmonary Fibrosis (IPF) is an inexorably progressive fibrotic lung disease with a variable and unpredictable rate of progression. CT scans of the lungs inform clinical assessment of IPF patients and contain pertinent information related to disease progression.
arxiv
Management of Idiopathic Pulmonary Fibrosis [PDF]
Clinics in Chest Medicine, 2012 Idiopathic pulmonary fibrosis (IPF) is a deadly progressive lung disease without an effective standard treatment approach. Because of the complexity and uncertainties of IPF treatment, therapeutic decisions need to be tailored to the individual patient, after discussing the potential benefits and pitfalls.
CERRI, Stefania +3 more
openaire +6 more sources